Jump to content

AIM2

From Wikipedia, the free encyclopedia

AIM2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesAIM2, PYHIN4, absent in melanoma 2
External IDsOMIM: 604578; MGI: 2686159; HomoloGene: 83226; GeneCards: AIM2; OMA:AIM2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

9447

383619

Ensembl

ENSG00000163568

ENSMUSG00000037860

UniProt

O14862

Q91VJ1

RefSeq (mRNA)

NM_004833
NM_001348247

NM_001013779

RefSeq (protein)

NP_004824
NP_001335176

NP_001013801

Location (UCSC)Chr 1: 159.06 – 159.19 MbChr 1: 173.35 – 173.47 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Interferon-inducible protein AIM2 also known as absent in melanoma 2 or simply AIM2 is a protein that in humans is encoded by the AIM2 gene.[5][6]

AIM2 is a cytoplasmic sensor found in hematopoietic cells that recognizes the presence of double-stranded DNA (dsDNA) of microbial or host cellular origin.[7] AIM2-like receptor (ALR) family was founded on AIM2 and now consists of four members in human genome.[8] Activated AIM2 recruits apoptosis-associated speck-like protein containing a CARD (ASC), resulting in caspase-1 binding, and forming of AIM2 inflammasome. This signaling contributes to the defense against bacterial and viral DNA. The AIM2 inflammasome can also be an integral component of the AIM2-PANoptosome to drive PANoptosis. [9][10]

Structure

[edit]

Proteins belonging to ALR family usually contain an N-terminal pyrin (PYD) domain, and one or two HIN domains. AIM2 consists of two domains connected through a long linker: an N-terminal PYD domain (amino acids 1-87), and a C-terminal HIN-200 domain (amino acids 138–337). The PYD domain mediates homotypic protein-protein interaction, while the HIN domain binds to DNA with its two tandem oligonucleotide/oligosaccharide binding (OB) folds.[11]

Function

[edit]

AIM2 is a component of the innate immune system that functions as a cytoplasmic dsDNA sensor playing a role in antiviral and antibacterial defenses, as well as in autoimmune diseases involving self DNA. Together with the adaptor ASC protein AIM2 forms a caspase-1 activating complex known as the AIM2 inflammasome. This AIM2 inflammasome can also be an integral component of a larger cell death-inducing complex called the AIM2-PANoptosome that drives PANoptosis. [9][10]

The first step in the formation of AIM2 inflammasome is DNA binding. The HIN domain of AIM2 binds to both strands of B-form dsDNA (either viral, bacterial, or even host) in a sequence-independent manner. However, the DNA sequence must be at least 80 base pairs in length.[12] The interaction is mainly electrostatic, where positively charged amino acid residues are coordinating with phosphates and sugar moieties on DNA backbone. Binding of dsDNA displaces PYD domain, which then engages the downstream inflammasome adaptor protein ASC through homotypic PYD-PYD interactions.[13] ASC is a bipartite PYD-CARD-containing protein. CARD domain of ASC recruits procaspase-1 (CARD-CARD interaction) to the complex creating the basic structural elements of the AIM2 inflammasome. Caspase-1 autoactivates and processes cleavage of pro-IL-1β, pro-IL-18, and gasdermin D. The N-terminal fragment of gasdermin D induces pyroptosis that allows mature cytokines IL-1β, and IL-18 to be released from the cell.  

AIM2 can also induce PANoptosis, a prominent innate immune, inflammatory, and lytic cell death pathway initiated by innate immune sensors and driven by caspases and receptor-interacting protein kinases (RIPKs) through PANoptosomes. [14][15] PANoptosomes are multi-protein complexes assembled by germline-encoded pattern-recognition receptor(s) (PRRs) (innate immune sensor(s)) in response to pathogens, including bacterial, viral, and fungal infections, as well as pathogen-associated molecular patterns, damage-associated molecular patterns, cytokines, and homeostatic changes during infections, inflammatory conditions, and cancer. [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] To form the PANoptosome, the AIM2 inflammasome further interacts with caspase-8, FADD, RIPK3, and RIPK1 in response to specific pathogens, including Francisella novicida and herpes simplex virus 1 (HSV1), to drive PANoptosis.

Regulation

[edit]

Regulation of inflammasome assembly is essential for cellular homeostasis maintenance. AIM2 activation is inhibited by the mouse protein p202 that consists of two HIN domains and lacks the PYD. ASC protein is not recruited due to the absence of PYD domain. The HIN1 domain binds to DNA, whereas HIN2 domain interacts with AIM2. HIN2 domain does not block the DNA binding surface of AIM2, hence, DNA binding affinity of AIM2 remains unaffected. It is believed that binding of p202 to DNA and AIM2 might attain a balance between host defense and pathological DNA-induced inflammation. When both p202 and AIM2 are present in equal amounts, there is a competition for dsDNA binding.[30]

A novel transcript isoform of human IFI16-designated IFI16-β has been also shown to inhibit the AIM2 inflammasome assembly. Its domain structure is similar to that of mouse p202 as it contains two HIN domains. Analogously it interacts with AIM2, competes in dsDNA binding, and disrupts ASC recruitment.[31] According to studies of p202 and IFI16-β, it appears that proteins expressing two HIN domains bind to dsDNA more robustly than proteins containing a single HIN domain.[32]

Regarding post-translational modifications, there is limited knowledge. However, it has been reported that TRIM11 binds AIM2 and leads to its degradation. Hence, it might be a negative regulator of the AIM2 inflammasome.[33]

Clinical relevance

[edit]

A broad range of microbes is sensed by AIM2, leading to protective inflammasome- or PANoptosome-mediated host responses. Recent publications have shown that AIM2 inflammasome also plays roles in non-infectious diseases.

Infection

[edit]

Bacteria

[edit]

Bacterial DNA is released into the cytoplasm during infection of a host cell, where it is recognized by AIM2 and other cytoplasmic DNA sensors. AIM2 has been shown to recognize a number of pathogenic bacteria – Francisella tularensis, Listeria monocytogenes, Streptococcus pneumoniae, Mycobacterium species, Porphyromonas gingivalis, Staphylococcus aureus, Brucella abortus, and Chlamydia muridarum.[7] Type I IFNs augment the activity of the AIM2 inflammasome during bacterial infection.[34][35] In addition, AIM2 assembles the AIM2-PANoptosome complex in response to Francisella novicida, inducing inflammatory cell death, PANoptosis. [9]

Viruses

[edit]

AIM2 inflammasome plays a crucial role in the defense against viral infection as genetic material from DNA viruses that enter the cytoplasm can be recognized. However, AIM2 does not respond to all DNA viruses. To date, only mouse cytomegalovirus (MCMV), vaccinia virus, and human papillomaviruses have been observed to induce AIM2 inflammasome.[7] AIM2 also responds to herpes simplex virus 1 (HSV1), forming the AIM2-PANoptosome, which leads to PANoptosis. [9]

Other pathogens

[edit]

Moreover, AIM2 has been shown to mediate host defense to the fungal pathogen Aspergillus fumigatus[36] and the protozoan Plasmodium berghei.[37]

Cancer

[edit]

The gene encoding AIM2 was originally isolated from human melanoma cells.[5] AIM2 has been shown to suppress the development of tumors. However, the expression of AIM2 was observed to be differential in a range of tumor tissues suggesting that it may have unique roles in different cancer types. Recent studies investigating AIM2 function in cancer highlight the potential role of therapies inhibiting the AKT pathway in the treatment of cancer associated with AIM2 mutations.[7]

Inflammatory, autoimmune, and other pathological conditions

[edit]

The accumulation of DNA in the cytosol can serve as an endogenous danger signal triggering AIM2 inflammasome. Aberrant activation of AIM2 from self-DNA is a key driver of inflammatory and autoimmune diseases. Elevated levels of AIM2 expression are found in skin cells from people with acute and chronic skin conditions, including psoriasis, atopic dermatitis, and contact dermatitis. Increased expression of AIM2 has also been reported in patients with inflammatory bowel disease and liver inflammation. Moreover, AIM2 might be involved in inflammation and cell death of the brain.[7] In systemic lupus erythematosus, lysosome dysfunction allows DNA to gain access to the cytosol and activate AIM2 resulting in increased type 1 interferon production.[38]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000163568 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000037860 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b DeYoung KL, Ray ME, Su YA, Anzick SL, Johnstone RW, Trapani JA, et al. (July 1997). "Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma". Oncogene. 15 (4): 453–7. doi:10.1038/sj.onc.1201206. PMID 9242382. S2CID 11152041.
  6. ^ "Entrez Gene: AIM2 absent in melanoma 2".
  7. ^ a b c d e Man SM, Karki R, Kanneganti TD (February 2016). "AIM2 inflammasome in infection, cancer, and autoimmunity: Role in DNA sensing, inflammation, and innate immunity". European Journal of Immunology. 46 (2): 269–80. doi:10.1002/eji.201545839. PMC 4758349. PMID 26626159.
  8. ^ Cridland JA, Curley EZ, Wykes MN, Schroder K, Sweet MJ, Roberts TL, et al. (August 2012). "The mammalian PYHIN gene family: phylogeny, evolution and expression". BMC Evolutionary Biology. 12 (1): 140. Bibcode:2012BMCEE..12..140C. doi:10.1186/1471-2148-12-140. PMC 3458909. PMID 22871040.
  9. ^ a b c d Lee S, Karki R, Wang Y, Nguyen LN, Kalathur RC, Kanneganti TD (2021-09-01). "AIM2 forms a complex with Pyrin and ZBP1 to drive PANoptosis and host defense". Nature. 597 (7876): 415–419. Bibcode:2021Natur.597..415L. doi:10.1038/s41586-021-03875-8. PMC 8603942. PMID 34471287.
  10. ^ a b "The PANoptosome: a new frontier in innate immune responses". www.stjude.org. Retrieved 2024-08-19.
  11. ^ Wang B, Yin Q (December 2017). "AIM2 inflammasome activation and regulation: A structural perspective". Journal of Structural Biology. 200 (3): 279–282. doi:10.1016/j.jsb.2017.08.001. PMC 5733693. PMID 28813641.
  12. ^ Jin T, Perry A, Jiang J, Smith P, Curry JA, Unterholzner L, et al. (April 2012). "Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor". Immunity. 36 (4): 561–71. doi:10.1016/j.immuni.2012.02.014. PMC 3334467. PMID 22483801.
  13. ^ Morrone SR, Matyszewski M, Yu X, Delannoy M, Egelman EH, Sohn J (July 2015). "Assembly-driven activation of the AIM2 foreign-dsDNA sensor provides a polymerization template for downstream ASC". Nature Communications. 6 (1): 7827. Bibcode:2015NatCo...6.7827M. doi:10.1038/ncomms8827. PMC 4525163. PMID 26197926.
  14. ^ "St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases". www.stjude.org. Retrieved 2024-08-19.
  15. ^ a b Pandeya A, Kanneganti TD (2024-01-30). "Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes". Trends Mol Med. 30 (1): 74–88. doi:10.1016/j.molmed.2023.10.001. PMC 10842719. PMID 37977994.
  16. ^ "Promising preclinical cancer therapy harnesses a newly discovered cell death pathway". www.stjude.org. Retrieved 2024-08-19.
  17. ^ "ZBP1 links interferon treatment and dangerous inflammatory cell death during COVID-19". www.stjude.org. Retrieved 2024-08-19.
  18. ^ "The PANoptosome: a new frontier in innate immune responses". www.stjude.org. Retrieved 2024-08-19.
  19. ^ "In the lab, St. Jude scientists identify possible COVID-19 treatment". www.stjude.org. Retrieved 2024-08-19.
  20. ^ "Discovering the secrets of the enigmatic caspase-6". www.stjude.org. Retrieved 2024-08-19.
  21. ^ "Breaking the dogma: Key cell death regulator has more than one way to get the job done". www.stjude.org. Retrieved 2024-08-19.
  22. ^ Kuriakose T, Man SM, Malireddi RS, Karki R, Kesavardhana S, Place DE, Neale G, Vogel P, Kanneganti TD (2016-08-05). "ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways". Sci Immunol. 1 (2). doi:10.1126/sciimmunol.aag2045. PMC 5131924. PMID 27917412.
  23. ^ Karki R, Sharma BR, Lee E, Banoth B, Malireddi RS, Samit P, Tuladhar S, Mummareddy H, Burton AR, Vogel P, Kanneganti TD (2020-06-18). "Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer". JCI Insight. 5 (12). doi:10.1172/jci.insight.136720. PMC 7406299. PMID 32554929.
  24. ^ "Diet affects mix of intestinal bacteria and the risk of inflammatory bone disease". www.stjude.org. Retrieved 2024-08-19.
  25. ^ Malireddi RS, Karki R, Sundaram B, Kancharana B, Lee S, Samir P, Kanneganti TD (2022-01-21). "Inflammatory cell death, PANoptosis, mediated by cytokines in diverse cancer lineages inhibits tumor growth". Immunohorizons. 5 (7): 568–580. doi:10.4049/immunohorizons.2100059. PMC 8522052. PMID 34290111.
  26. ^ Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samit P, Zheng M, Sundaram B, Banoth B, Malireddi RS, Schreiner P, Vogel P, Webby R, Jonsson CB, Kanneganti TD (2020-11-19). "Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes". Cell. 184 (1): 149–168. bioRxiv 10.1101/2020.10.29.361048. doi:10.1016/j.cell.2020.11.025. PMID 33278357.
  27. ^ Karki R, Lee S, Mall R, Pandian N, Wang Y, Sharma BR, Malireddi RS, Yang D, Steele JA, Connelly JP, Vogel P, Pruett-Miller SM, Webby R, Jonsson CB, Kanneganti TD (2022-05-19). "ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection". Sci Immunol. 19 (eabo6294): eabo6294. doi:10.1126/sciimmunol.abo6294. PMC 9161373. PMID 35587515.
  28. ^ Wang Y, Pandian N, Han JH, Sundaram B, Lee S, Karki R, Guy CS, Kanneganti TD (2023-09-28). "Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method". Cell Mol Life Sci. 79 (10): 531. doi:10.1007/s00018-022-04564-z. PMC 9545391. PMID 36169732.
  29. ^ Sundaram B, Pandian N, Mall R, Wang Y, Sarkar R, Kim HJ, Malireddi RS, Karki R, Janke LJ, Vogel P, Kanneganti TD (2024-06-22). "NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs". Cell. 186 (13): 2783–2801. doi:10.1016/j.cell.2023.05.005. PMC 10330523. PMID 37267949.
  30. ^ Ru H, Ni X, Zhao L, Crowley C, Ding W, Hung LW, et al. (June 2013). "Structural basis for termination of AIM2-mediated signaling by p202". Cell Research. 23 (6): 855–8. doi:10.1038/cr.2013.52. PMC 3674390. PMID 23567559.
  31. ^ Wang PH, Ye ZW, Deng JJ, Siu KL, Gao WW, Chaudhary V, et al. (October 2018). "Inhibition of AIM2 inflammasome activation by a novel transcript isoform of IFI16". EMBO Reports. 19 (10). doi:10.15252/embr.201845737. PMC 6172465. PMID 30104205.
  32. ^ Sharma M, de Alba E (January 2021). "Structure, Activation and Regulation of NLRP3 and AIM2 Inflammasomes". International Journal of Molecular Sciences. 22 (2): 872. doi:10.3390/ijms22020872. PMC 7830601. PMID 33467177.
  33. ^ Yang J, Liu Z, Xiao TS (January 2017). "Post-translational regulation of inflammasomes". Cellular & Molecular Immunology. 14 (1): 65–79. doi:10.1038/cmi.2016.29. PMC 5214939. PMID 27345727.
  34. ^ Henry T, Brotcke A, Weiss DS, Thompson LJ, Monack DM (May 2007). "Type I interferon signaling is required for activation of the inflammasome during Francisella infection". The Journal of Experimental Medicine. 204 (5): 987–94. doi:10.1084/jem.20062665. PMC 2118578. PMID 17452523.
  35. ^ Fang R, Hara H, Sakai S, Hernandez-Cuellar E, Mitsuyama M, Kawamura I, Tsuchiya K (June 2014). Camilli A (ed.). "Type I interferon signaling regulates activation of the absent in melanoma 2 inflammasome during Streptococcus pneumoniae infection". Infection and Immunity. 82 (6): 2310–7. doi:10.1128/IAI.01572-14. PMC 4019145. PMID 24643540.
  36. ^ Karki R, Man SM, Malireddi RK, Gurung P, Vogel P, Lamkanfi M, Kanneganti TD (March 2015). "Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against Aspergillus infection". Cell Host & Microbe. 17 (3): 357–368. doi:10.1016/j.chom.2015.01.006. PMC 4359672. PMID 25704009.
  37. ^ Kalantari P, DeOliveira RB, Chan J, Corbett Y, Rathinam V, Stutz A, et al. (January 2014). "Dual engagement of the NLRP3 and AIM2 inflammasomes by plasmodium-derived hemozoin and DNA during malaria". Cell Reports. 6 (1): 196–210. doi:10.1016/j.celrep.2013.12.014. PMC 4105362. PMID 24388751.
  38. ^ Monteith AJ, Kang S, Scott E, Hillman K, Rajfur Z, Jacobson K, et al. (April 2016). "Defects in lysosomal maturation facilitate the activation of innate sensors in systemic lupus erythematosus". Proceedings of the National Academy of Sciences of the United States of America. 113 (15): E2142-51. Bibcode:2016PNAS..113E2142M. doi:10.1073/pnas.1513943113. PMC 4839468. PMID 27035940.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=AIM2&oldid=1263462841"